4192.Two
4192.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
Business. 4192.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4192.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.
4192.TWO maintains a strong liquidity position, with a current ratio of 21.37, indicating a significant excess of current assets over current liabilities. The company holds TWD 157,334,000 in cash and equivalents, which is a substantial portion of its total assets of TWD 255,702,000. The low debt-to-equity ratio of 0.01 suggests minimal reliance on debt financing, further supporting its liquidity profile.
The company's profitability is currently negative, with a return on equity of -18.63% and a return on assets of -17.89%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating loss of TWD 47,196,000 and net loss of TWD 45,755,000 highlight the challenges in achieving profitability.
There is no detailed information available on the company's segments or geographic exposure. However, the revenue concentration data is not provided, making it difficult to assess the diversification of its revenue streams. The company's primary business activity is in pharmaceuticals and medical research, but the specific geographic regions or product lines contributing to its revenue are not disclosed.
The company's growth trajectory is currently negative, with a net loss and operating loss in the latest financial period. The operating cash flow of TWD -38,333,000 and free cash flow of TWD -28,581,000 indicate that the company is not generating positive cash flows from operations. The capital expenditure of TWD -406,000 suggests minimal investment in long-term assets, which may impact future growth.
The risk assessment indicates low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags detected. The company's low debt-to-equity ratio and substantial cash reserves reduce the likelihood of financial distress. However, the negative profitability metrics suggest that the company may need to raise additional capital in the future, which could lead to dilution for existing shareholders.
There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The absence of recent transcripts or filings suggests a lack of public disclosures that could provide further insight into the company's strategic direction or operational performance.
- 4192.TWO has a strong liquidity position with a current ratio of 21.37 and TWD 157,334,000 in cash and equivalents.
- The company is currently unprofitable, with a return on equity of -18.63% and a return on assets of -17.89%.
- There is no detailed information on the company's segments or geographic exposure, limiting the understanding of its revenue diversification.
- The company's growth trajectory is negative, with a net loss and operating loss in the latest financial period.
- The risk assessment indicates low liquidity and dilution risks, but the negative profitability metrics suggest potential future capital needs.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4192.TWO Market data — financials · 2026-05-26